(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Terapia celular > DA - CIMA - Oncología - Terapia celular - Artículos de Revista >

CpG IslandMethylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia
Autor(es) : Roman-Gomez, J. (José)
Jimenez-Velasco, A. (A.)
Aguirre, X. (Xavier)
Castillejo, J.A. (J.A.)
Navarro, G. (Germán)
Calasanz-Abinzano, M.J. (Maria Jose)
Garate, L. (Leire)
San-Jose, E. (Edurne)
Cordeu, L. (Lucía)
Prosper, F. (Felipe)
Heiniger, A. (A.)
Torres, A. (Antonio)
Palabras clave : Materias Investigacion::Ciencias de la Salud::Oncología
Fecha incorporación: 2006
Editorial : American Association for Cancer Research
Versión del editor: http://dx.doi.org/10.1158/1078-0432.CCR-05-2592
ISSN: 1078-0432
Cita: Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Castillejo, J. A. et al. CpG IslandMethylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia. Clin Cancer Res 2006; 12; 4845
Resumen
Purpose: To examine cancer genes undergoing epigenetic inactivation in a set of ETV6/ RUNX1-positive acute lymphoblastic leukemias in order to define the CpG island methylator phenotype (CIMP) in the disease and evaluate its relationship with clinical features and outcome. Experimental Design: Methylation-specific PCRwas used to analyze themethylation status of 38 genes involved in cell immortalization and transformation in 54 ETV6/RUNX1-positive samples in comparison with190 ETV6/RUNX1-negative samples. Results: ETV6/RUNX1-positive samples had at least one gene methylated in 89% of the cases. According to the number of methylated genes observed in each individual sample, 20 patients (37%) were included in the CIMP group (0-2 methylated genes) and 34 (67%) in the CIMP+ group (>2 methylated genes). Remission rate did not differ significantly among either group of patients. Estimated disease-free survival and overall survival at 9 years were 92% and 100% for the CIMP group and 33% and 73% for the CIMP+ group (P =0.002andP = 0.04, respectively). Multivariate analysis showed that methylation profile was an independent prognostic factor in predicting disease-free survival (P = 0.01) and overall survival (P = 0.05). A group of four genes (DKK3, sFRP2, PTEN, andP73) showed specificity for ETV6/RUNX1-positive subset of samples. Conclusion: Our results suggest that methylation profile may be a potential new biomarker of risk prediction in ETV6/RUNX1-positive acute lymphoblastic leukemias.
Enlace permanente: http://hdl.handle.net/10171/18358
Aparece en las colecciones: DA - CIMA - Oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Oncología - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Ficheros en este registro:

No hay ficheros asociados a este ítem.

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.